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This study investigated the effect of age and that of the post-ovariectomy (OVX) time
interval on the antidepressant (AD)-like effects of estradiol (E2) and selective serotonin
reuptake inhibitors (SSRIs) in middle-aged (10 month) OVX rats (10m-OVX). Acute or
chronic effects of these treatments in 10m-OVX were compared with those (1) in young
adult (4-month) OVX rats (4m-OVX) or with older (14-month) OVX rats (14m-OVX), at a
short time: 2 weeks post-OVX (+2w) and (2) in 10m-OVX rats after a longer times: 4 or 8
months post-OVX (+4m or +8m). Using in vivo chronoamperometry in the CA3 region
of the hippocampus, E2 at 20 pmol, a dose shown previously to inhibit the serotonin
transporter (SERT) in 4m-OVX, had no effect in 10m-OVX+2w. A higher dose of E2
(40 pmol) increased T80 value, a measure of serotonin or 5-hydroxytryptamine (5-HT)
clearance, and also blocked the ability of fluvoxamine to increase T80. By contrast,
estradiol had no effects on SERT function in 10m-OVX+4m, even at a higher dose than
40 pmol. Fluvoxamine slowed 5-HT clearance in 10m-OVX at +2w, +4m and +8m
post-OVX as it did in the 4m-OVX. Using the forced swim test, 2 weeks treatment with
E2 (5 µg/day), a dose shown previously to induce AD-like effects in 4m-OVX, had no
effect in 10m-OVX+2w. However, a higher dose (10 µg/day) of E2 induced an AD-like
effect as demonstrated by significantly increased swimming behavior and decreased
immobility. This effect was not seen in 10m-OVX+4m. By contrast, significant AD-like
effects were obtained in 14m-OVX+2w, thereby demonstrating that the lack of an AD
effect of E2 is due to the 4-month hormone withdrawal and not to an age effect. After
2 weeks treatment with the SSRI sertraline, similar AD-like effects were obtained in
10m-OVX tested at +2w, +4m or +8m post-OVX as those found in 4m-OVX. Thus,
the potency of estradiol to produce effects consistent with inhibition of the SERT was
not only decreased in older rats but its effects were markedly diminished the longer
hormonal depletion occurred. By contrast, the ability of SSRIs to inhibit the SERT was
not affected either by age or the length of hormonal depletion.
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INTRODUCTION
The efficacy of antidepressants (ADs) in the elderly suffering
from major depressive disorder (MDD) is controversial (Kasper
et al., 2005; Nelson et al., 2008). Although tricyclic ADs and
selective serotonin reuptake inhibitors (SSRIs) are reported to be
effective in clinical trials with older patients (Gareri et al., 2000;
Salzman et al., 2002; Blazer, 2003) some authors have claimed that
their effectiveness is reduced compared to that found in young
adults (Lenze et al., 2008; Sheffrin et al., 2009; Tedeschini et al.,
2011). Moreover, it has been suggested that such decline begins at
middle age as a modest reduction that becomes more pronounced
at senescence (Tedeschini et al., 2011).
MDD occurs about twice as frequently in women as in men
(Kupfer et al., 2012), with increased occurrence in middle age,
around the menopausal transition (Maartens et al., 2002). In
fact, the onset or exacerbation of depressive symptoms has been
associated with the time around perimenopause (Maki et al.,
2010; Soares, 2013). This has provided a rationale to try either
estrogen replacement therapy (ERT) or hormone replacement
therapy (HRT) in such patients. Such treatment has been reported
to have AD effects in peri- and postmenopausal women (Frey
et al., 2008; Soares and Frey, 2010), although this is not a
universal finding (Morrison et al., 2004). ADs are also used to
treat depression in menopausal women. Some reports indicate
that the AD response could be modified not only by aging but also
the endocrine condition. Although some find pre-menopausal
women are more responsive than post-menopausal women to
ADs (Soares et al., 2001; Huang et al., 2008; Pae et al., 2009),
this is not a universal finding (Kornstein et al., 2013, 2015).
A combination of estrogen and AD is also often used to treat
depression in menopausal women. However, there appears to
be little evidence that taking SSRIs in conjunction with ERT
produces greater improvement in depressive symptoms than that
seen with an SSRI alone (Frey et al., 2008).
A possible reason for such discrepancy in results is the time
when AD treatment was started in relation to menopause onset.
A “window of opportunity” or “the critical period” hypothesis has
been postulated for the effects of estrogen (Rocca et al., 2011),
which proposes that ERT is only beneficial if administration is
begun during a time window in close proximity to menopause
(Resnick and Henderson, 2002). Many studies have examined
the critical period hypothesis for estradiol’s effects with respect
to cognition but only a few clinical studies have investigated
the effect of the time of initiation of ERT and/or AD therapy
after menopause in mood disorders (Craig, 2013). It has been
suggested that menopausal status and old age are predictors of
a poor response to AD treatment (Pae et al., 2009).
The aims of the present study were to explore whether the
age (4-month, 10-month, and 14-month OVX rats) and/or post-
OVX interval (2 weeks versus 4 months or 8 months) influences
the AD effect of estradiol and that of SSRIs in middle-aged 10-
month OVX rats. Many studies primarily examined the acute
effects of estradiol or ADs in middle-aged rats; however, such
treatments are given chronically to post-menopausal depressed
patients. Therefore, this study examined not only the acute
effects of E2 and of SSRI, using chronoamperometry to provide
a direct measure of the effect of local application of an SSRI into
the CA3 region of the hippocampus on serotonin transporter
(SERT) function, but also the behavioral consequences of chronic
treatments with estradiol and with SSRIs in the forced swim
test (FST). The FST provides a behaviorally relevant but more
indirect measure of the effect of the treatments on SERT function
(Cryan et al., 2002). Chronoamperometry experiments, as stated
above, are carried out in the CA3 region of hippocampus. This
specific area of hippocampus was selected based on earlier work
showing that under our experimental conditions active clearance
of exogenous 5-hydroxytryptamine (5-HT) from it was due
exclusively to the SERT (Daws et al., 1998). The hippocampus,
in general, is an appropriate area to study AD effects on SERT
function and the influence of ovarian steroids on such effects.
It receives a dense serotonergic innervation, with perhaps some
preferential innervation from the median raphe (Jacobs and
Azmitia, 1992). There is an abundance of data indicating that
the SERT is the key, initial cellular target for SSRIs (Lenox and
Frazer, 2002). Also, estrogen is known to affect the anatomy
and physiology of the rodent hippocampus (McEwen and Alves,
1999). There are substantial estrogen receptor (ER)α and ERβ
protein in the hippocampus in general and in CA3 in particular
(Shughrue and Merchenthaler, 2000). In addition, both the
anatomy and function of the hippocampus are affected by AD
treatment (Castrén and Rantamäki, 2010; Duman and Li, 2012).
MATERIALS AND METHODS
Animals
Ovariectomized (OVX) rats (Sprague-Dawley; 4-month, 10-
month, and 14-month-old, Envigo, Indianapolis, IN, USA) were
housed on a 12 h:12 h light/dark cycle with lights on at 07:00 and
with food and water provided ad libitum. All animal procedures
were in accordance with the National Institutes of Health Guide
for the Care and Use of Laboratory Animals and were approved
by the local Institutional Animal Care and Use Committee. All
efforts were made to minimize the number of animals used, or
stress and discomfort to the animals during the experimental
procedure. In general, OVX rats (4-month, 10-month, and 14-
month) were used 2 weeks after ovariectomy (to allow recovery
after surgery before the start of the experiment). However, in
studies investigating the effect of time post-OVX, 10–month-old
OVX rats were also used 4 months or 8 months post-ovariectomy.
Choice of Animal Model
The incidence of regular estrous cyclicity decreases progressively
during aging. Between 8 and 12 months of age, female Sprague-
Dawley rats display prolonged irregular cycles (Matt et al., 1986),
a period named periestropause or recurrent pseudopregnancy
and is characterized by high levels of follicle-stimulating
hormone (FSH) and luteinizing hormone (LH) in comparison
with those in young female rats in diestrus (Bestetti et al.,
1991). This stage is analogous to perimenopause or menopause
transition in women where menstrual cycle irregularities are
related to increased levels in FSH and LH (Prior, 1998). The
state of complete loss of reproductive capacity in rodents,
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called estropause, is characterized by persistent diestrus. Lower
levels of estradiol (Bestetti et al., 1991) as well as higher levels
(Wise and Ratner, 1980; Gore et al., 2000) were reported
in middle-aged rats in persistent diestrus as compared with
young females in the same estrous-cycle phase. These differences
seem to depend upon the strain of rat, age and sensitivity
of the hormone assay. Rat estropause differs from monkey
and human menopause in that aged rats retain a much larger
number of primary oocytes, resulting in higher estrogen levels
at the onset of persistent diestrus than those seen in primates
after menopause (Chakraborty and Gore, 2004). To limit this
difference, in this study rats entering estropause (10–month-
old) were ovariectomized thus providing a model that mimics
better both the age and ovarian hormone status of peri- and
postmenopausal women.
Choice of SSRIs Used in Acute and
Chronic Studies
For the acute studies, the SSRI fluvoxamine was used in the
in vivo chronoamperometry experiments as we found that it did
not interfere with the electrochemical signal of 5-HT as other
SSRIs such as fluoxetine or sertraline did. However, fluvoxamine-
induced effects observed in such experiments were not specific
to it, but also occurred with another SSRI, citalopram, which was
also devoid of electrochemical effects on its own (Benmansour
et al., 2009).
For chronic studies of AD-like effects, fluvoxamine was not
used because it is very expensive such that the cost for chronic
administration would be prohibitive; further, is not the Food and
Drug Administration (FDA)-approved in the USA for treatment
of depression whereas sertraline is. We have selected a dose of
sertraline that has been shown not only to downregulate the
SERT but also to produce AD-like effects in the FST when
given chronically to male rats (Benmansour et al., 1999; Bilge
et al., 2008; Furmaga et al., 2011) as well as to female OVX rats
(Benmansour et al., 2016).
Experimental Design and Drug Treatment
In the acute and chronic estradiol experiments, two middle-
aged groups—10 months and 14 months—were used 2 weeks
post-OVX. The impact of the length of hormonal depletion was
studied in 10-month OVX rats by measuring effects at 2 weeks
and 4 months post-OVX.
In the acute and chronic SSRI experiments, two age groups
were used—young adult (4-month) and middle-aged (10 month),
with both used 2 weeks post-OVX. The impact of the length of
hormonal depletion was studied also in 10-month OVX rats by
measuring effects at 2 weeks, 4 months, or 8 months post-OVX.
Therefore, there were the following groups in the acute or
chronic experiments:
(1) 4-month OVX, used 2 weeks post-ovariectomy (4m-
OVX+2w)
(2) 10-month OVX, used 2 weeks post-ovariectomy (10m-
OVX+2w)
(3) 14-month OVX, used 2 weeks post-ovariectomy (14m-
OVX+2w)
(4) 10-month OVX, used 4 months post-ovariectomy (10m-
OVX+4m)
(5) 10-month OVX, used 8 months post-ovariectomy (10m-
OVX+8m)
For the chronic estradiol experiments, four cohorts of 13–
16 rats each were used, 6–8 controls, and 7–8 estradiol-treated
animals (groups 2, 3, and 4). Estradiol (5 or 10 µg/day
for group 2) and (10 µg/day for groups 3 and 4) was
administered for 2 weeks subcutaneously via implantation of
osmotic minipumps. Control groups received vehicle which
consisted of 25% EtOH/H2O.
For the chronic sertraline experiments, four cohorts of
16 rats each were used, 8 controls and 8 sertraline-treated
animals (groups 1, 2, 4, and 5). Sertraline was administered
(10 mg/kg/day) subcutaneously via implantation of osmotic
minipumps. Control groups received vehicle which consisted of
25% EtOH/H2O.
In vivo Chronoamperometry
This was carried out as described previously (Benmansour et al.,
2012).
Animal Preparation
All groups of Sprague-Dawley OVX rats were anesthetized
with chloralose (70 mg/kg)/urethane (700 mg/kg) administered
intraperitoneally, after tracheal intubation and placed into a
stereotaxic apparatus (David Kopf Instruments). The body
temperature of the rat was maintained between 37 and 38◦C
using a water-circulating heating pad. The scalp was incised and
reflected and a hole drilled in the skull at the desired coordinates.
A small burr hole was drilled over the posterior cortex for
placement of Ag/AgCl reference electrode.
Electrode Preparation
Carbon fiber electrodes (30 µm tip diameter, 95–175 µm in
length) were coated with Nafion to improve their selectivity, then
tested for sensitivity to 5-hydroxyindoleacetic acid (250 µM) and
calibrated in vitro with 5-HT.
Micropipette Preparation
The carbon fiber electrode was positioned adjacent to a four
barrel micropipette with the tip separation between 250 and
350 µm. The electrode and the multibarrel micropipette were
then attached using sticky wax. Micropipette barrels were filled
with 5-HT (200 µM, Sigma-Aldrich, St Louis, MO, USA),
fluvoxamine (400 µM, Sigma-Aldrich, St Louis, MO, USA;
fluvoxamine was always used at 4× the amount of 5-HT applied),
or 17-β-estradiol (E2, Sigma-Aldrich, St Louis, MO, USA). Drugs
were prepared in 0.1 M phosphate-buffered saline (PBS) and
supplemented with 100 µM ascorbic acid. The pH of all solutions
was 7.4. All drugs were delivered by pressure ejection in a volume
of 20–100 nl, using a PLI-100 reproducible pico-injector.
Electrochemical Recordings
The electrode-pipette assembly was lowered into the CA3
region of the hippocampus [stereotaxic coordinates (mm)
anterior–posterior, −4.10 from bregma; medio-lateral, +3.30
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from midline; dorsal–ventral, −3.60 from dura; Paxinos and
Watson, 1986]. Chronoamperometric recordings were started
20–30 min after the lowering of the assembly to allow
the baseline electrochemical signal to stabilize. High-speed
chronoamperometric recordings were made using the Fast-16
system (Quanteon). Oxidation potentials consist of 100 ms pulses
of +0.55 V versus Ag/AgCl were delivered one per second; the
electrode was held at the resting potential of 0.0 V between
measurements. Oxidation and reduction currents were digitally
integrated during the last 80 ms of each 100 ms voltage pulse.
The ability of fluvoxamine to block 5-HT clearance was
measured after the 5-HT signal became stable. The effects
of estradiol on 5-HT clearance and on fluvoxamine-induced
blockade of 5-HT clearance were measured 1–10 min and 40–
60 min post-E2 application. Several parameters are obtained from
the electrochemical signal produced by exogenous applications of
5-HT. Analyzed in this study is the clearance time parameter, T80
which is the time required for the peak amplitude to be reduced
by 80% (see Figure 1).
Forced Swimming Test
A modified FST procedure from the one described by Cryan
et al. (2002) was used. On day 15 of chronic treatment (while
estradiol or sertraline were still administered), a swim test session
of 5 min was carried out with no pretest session. This approach
is used in order to avoid the extended delay (2 weeks) between
the first (pretest) and the second exposure (test) or the impact
of drugs being present during the pretest session if pretest and
test are separated by the usual 24 h. In addition, it has been
shown that positive results with the drugs could be obtained
even if no training session was carried out (Cryan et al., 2005;
Benmansour et al., 2016). Rats were placed individually into
FIGURE 1 | Representative 5-hydroxytryptamine (5-HT)
electrochemical signals illustrating the effect of locally applied 17-β
estradiol into the CA3 region of the hippocampus of an OVX rat. The
signal was generated by local application of 5-HT (5.2 pmol). Estradiol
40 pmol was pressure ejected 10 min before the next application of 5-HT.
Shown here is the clearance time, T80 parameter: the time it takes for the
peak signal amplitude to be reduced by 80%. For clarity, only oxidation signals
are shown.
a Plexiglas cylinder (21 × 46 cm) filled with 25◦C water to a
depth of 40-cm. As the older rats are heavier than the younger
ones (4m-OVX+2w: 295 ± 2 g; 10m-OVX+2w: 314 ± 3 g;
14m-OVX+2w: 332± 6 g; 10m-OVX+4m: 362± 10 g; and 10m-
OVX+8m: 400 ± 11 g) the depth of the water in the tank was
adjusted so as not to compromise their swimming in the FST,
e.g., 40 cm instead of 30 cm such that animals could not place
their rear paws on the bottom without being totally submersed.
Behaviors during the 5 min swim were recorded by a video
camera positioned above the tank. A time sampling technique
was employed whereby the predominant behavior in each 5 s
bin of the test was analyzed. Climbing was defined as upward-
directed movements of the forepaws along the side of the swim
chamber. Swimming was defined as active movements (usually
horizontal) throughout the swim chamber, which also include
crossing into another quadrant. Immobility is assigned when
no active movement other than that necessary to keep the rat’s
head above the water. The rater was blind with respect to the
experimental conditions being scored.
Serum Levels of Sertraline and Its
Metabolite
At the end of the FST session serum was collected from all
treatment groups. Serum concentrations of sertraline and
desmethyl-sertraline were determined by high performance
liquid chromatography (HPLC) as described previously
(Benmansour et al., 1999).
Statistical Analysis
Data were analyzed using SigmaStats (Systat Software Inc, San
Jose, CA, USA). Kruskal–Wallis one-way analysis of variance
(ANOVA) on ranks, followed by Dunn’s post hoc analysis was
used to compare percent change in T80 values caused either by
E2, fluvoxamine, or E2 plus fluvoxamine (Figure 2). Two-way
ANOVA followed by Dunnett’s analysis was used to compare (1)
effect of age or time post-OVX within the vehicle and within the
E2 or the sertraline groups, and (2) effect of E2 or sertraline within
the age groups and within time post-OVX groups (Figures 3
and 5; Table 1). Paired Student’s t-test was used when comparing
T80 value post-fluvoxamine with T80 value pre-fluvoxamine in
the same animal (Figure 4). One-way ANOVA was also used in
Figure 4 comparing T80 values pre-fluvoxamine and values post-
fluvoxamine among all groups. Only when there was a significant
main effect and/or interaction effect in the ANOVA’s were post
hoc analyses carried out. Significance was determined at p< 0.05.
RESULTS
Effects of Local Application of Estradiol
on SERT Function
The clearance time parameter, T80, derived from the generated
5-HT electrochemical signal, was analyzed in this study and is
represented in Figure 1. In 4-month OVX rats, E2 (20 pmol)
was shown previously to produce both early (1–10 min post-
E2) and late (40–60 min post-E2) effects, i.e., it increased the
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FIGURE 2 | Effects of acute estradiol administration on serotonin
transporter (SERT) function in middle-aged OVX rats at different
interval times post-OVX. Estradiol (40 or 60 pmol) was locally applied into
the CA3 region of the hippocampus of 10m-OVX+2w and 10m-OVX+4m and
its effects measured at an early time point (1–10 min) and later time point
(40–60 min) post-E2 administration on: (A) 5-HT clearance: the 5-HT
clearance time parameter, T80, was analyzed pre-E2, 1–10 min post-E2 and
40–60 min post-E2. Bar and brackets represent the T80 value as a percentage
of the pre-treatment value ± SEM (n = 7–8). ∗p < 0.05, Kruskal–Wallis
one-way ANOVA on ranks, followed by Dunn’s test comparing percent
change in T80 values 1–10 min and 40–60 min post-E2 with the percent
change in T80 value in the corresponding pre-E2 value. (B) The ability of
fluvoxamine to slow 5-HT clearance: as shown by an increase in the T80
value. Fluvoxamine (4× the amount of 5-HT) was pressure ejected 60–90 s
before the second application of 5-HT. Bar and brackets represent the
percent change in the T80 value after fluvoxamine ± SEM (n = 6–10).
∗p < 0.05, Kruskal–Wallis one-way analysis of variance on ranks, followed by
Dunn’s test comparing percent change in the T80 value post-fluvoxamine
1–10 min and 40–60 min after E2 with fluvoxamine’s percent change in the
T80 value of the corresponding pre-E2 value.
T80 value (a measure of 5-HT clearance) and also blocked the
fluvoxamine-induced increase in the T80 value (Benmansour
et al., 2009, 2012). At that same dose in 10-month OVX rats, E2
had no effect on 5-HT clearance nor did it alter the ability of
fluvoxamine to slow 5-HT clearance (Figures 2A,B, left panel).
However, a higher dose of E2 (40 pmol) increased the T80 value
but this effect was only seen 40–60 min post-application of E2
(Figure 2A, left panel). Fluvoxamine significantly increased the
T80 value (to 140± 6% of the control value) in middle aged OVX
rats. Administration of 20 pmol of E2 produced no inhibition
of the fluvoxamine effect (Figure 2B, left panel). However, the
higher amount of E2, 40 pmol, did reduce significantly the effect
of fluvoxamine at 1–10 min after E2 application but not at 40–
60 min post-E2 (Figure 2B, left panel). By contrast after 4 months
of hormonal depletion, 40 pmol E2 had no effect on serotonin
clearance nor did it alter the ability of fluvoxamine to slow 5-
HT clearance in 10–month-old OVX rats. Increasing the dose
to 60 pmol also did not produce any effects on the parameters
measured (Figures 2A,B, right panel).
Effect of Long-Term Treatment with
Estradiol in the FST
The FST was used to investigate the longer-term effects of
E2, administered subcutaneously via osmotic minipumps for 2
weeks. In 4-month OVX rats, it was shown previously that long-
term E2 (5µg) induced an AD-like effect in the FST (Benmansour
et al., 2016). In 10-month OVX rats, E2 (5 µg) did not change
immobility or swimming behavior in the FST as compared to
that measured in control rats (data not shown). At a higher dose
(10 µg), E2 induced a significant decrease in immobility that
was associated with a significant increase in swimming behavior
(Figure 3, first panel). However, E2 (10 µg) had no effect in
10-month OVX rats when the treatment was started 4 months
post-OVX as opposed to 2 weeks post-OVX (Figure 3, second
panel). By contrast, significant AD-like effects were obtained in
14-month OVX rats tested 2 weeks after OVX (Figure 3, third
panel), thereby demonstrating that the lack of AD-like effects of
E2 is due to the 4-month hormone withdrawal and not to an age
effect.
Effect of Local Application of an SSRI on
SERT Function
This experiment was designed to examine the ability of the SSRI
fluvoxamine to inhibit SERT function in 10-month-old middle-
aged OVX rats in comparison to its effects in 4-month-old adult
OVX rats and to determine in the middle-aged rats if the time
after OVX when fluvoxamine is tested would influence its effects.
As expected, fluvoxamine prolonged the clearance time of 5-HT
in 4m-OVX+2w rats as shown by a significant increase in the
clearance time T80 value post-fluvoxamine compared with the
pre-fluvoxamine value (Figure 4). This is consistent with our
previous data in young adult OVX rats (Benmansour et al., 2009,
2012, 2014). Similarly, fluvoxamine significantly increased the
T80 value in 10m-OVX+2w, 10m-OVX+4m as well as 10m-
OVX+8m when compared to their pre-fluvoxamine T80 values
(Figure 4). Thus, fluvoxamine blocked SERT function in all the
groups with the effect not dependent on the time elapsed after
OVX.
Effect of Chronic Treatment with
Sertraline in the FST
The behavioral effects of chronic treatment with the SSRI
sertraline in the FST were examined in young adult and middle-
aged rats at short or longer times after OVX. As expected
and shown previously, in 4m-OVX+2w rats, chronic treatment
with sertraline induced an AD-like behavior in the FST, i.e.,
it significantly decreased immobility and increased swimming
behaviors as compared to that in control rats. Similarly, chronic
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FIGURE 3 | Effect of long-term treatment with estradiol in the FST. OVX rats (10m-OVX+2w, 10m-OVX+4m, and 14m-OVX+2w) were treated for 2 weeks
with estradiol (10 µg) via subcutaneous osmotic minipumps, as described in the Section “Materials and Methods.” Mean counts for immobility, swimming and
climbing behaviors were sampled every 5 s of the swim test period. Bars and brackets represent the mean value ± SEM, n = 6–8/group. Immobility (I): Two-way
ANOVAs were carried out between: (1) age and treatment (10m-OVX+2w and 14m-OVX+2w groups) and 2) between time post-OVX and treatment (10m-OVX+2w,
10m-OVX+4m). When comparing age/treatment, two-way ANOVA showed a significant main effect for treatment [F(1,24) = 28.23, p < 0.001] but no significant
effect for age or for interaction between age × treatment. When comparing time post-OVX /treatment, two-way ANOVA showed a significant main effects for
treatment [F(1,26) = 11.47, p < 0.01], for time post-OVX [F(1,26) = 8.13, p < 0.01] and for interaction between time post-OVX × treatment [F(1,26) = 8.13,
p < 0.01]. Dunnett’s post hoc analysis was carried out;∗p < 0.001, comparing treatment with E2 within 10m-OVX+2w and within 14m-OVX+2w with their
respective controls. Swimming (S): Two-way ANOVAs were carried out between: (1) age and treatment (10m-OVX+2w and 18m-OVX+2w groups) and (2) between
time post-OVX and treatment (10m-OVX+2w, 10m-OVX+4m). When comparing age/treatment, two-way ANOVA showed a significant main effect for treatment
[F(1,24) = 46.18, p < 0.001] but no significant effect for age or for interaction between age × treatment. When comparing time post-OVX/treatment, two-way
ANOVA showed a significant main effects for treatment [F(1,26) = 24.39, p < 0.001] and for interaction between time post-OVX × treatment [F(1,26) = 8.68,
p < 0.01] but no effect for time post-OVX. Dunnett’s post hoc analysis was carried out; ∗p < 0.001, comparing treatment with E2 within 10m-OVX+2w and within
14m-OVX+2w with their respective controls. Climbing (C): Two-way ANOVAs were carried out between age and treatment and between time post-OVX and
treatment. There were no significant effects in any of the analyses.
treatment with sertraline significantly decreased immobility and
increased swimming behaviors in middle-aged rats at 2 weeks,
4 months, or 8 months post-OVX (Figure 5). None of the
treatments altered climbing behavior. Although there was a trend
for the effects of sertraline (on both immobility and swimming)
to be of smaller magnitude in the 10m-OVX+4m and the 10m-
OVX+8m than the other groups, this difference did not reach
significance. There was no change in baseline behavior within
groups (Figure 5).
In addition serum levels of sertraline and its metabolite
desmethyl-sertraline were analyzed in each group after
conclusion of the FST. Neither sertraline levels nor the ratio of
desmethyl-sertraline/sertraline were significantly different in any
of the experimental groups. Although there was a trend for both
measurements to be higher in the 10m-OVX+4m than any of
the other groups, this was not statistically significant (Table 1).
DISCUSSION
These data show that (1) a higher dose of estradiol was necessary
to induce AD-like effects in middle-aged OVX rats as compared
to those needed in young adult OVX rats; (2) treatment with
SSRIs induced an AD-like effect in the middle-aged OVX rats
that was similar to that seen in younger adult OVX rats; (3)
AD-like effects of estradiol are dependent on the time interval
post-ovariectomy whereas the effects of SSRIs are not. Moreover,
such results are similar irrespective of whether they were obtained
using chronoamperometry to measure SERT function directly in
the CA3 region of the hippocampus or the FST to measure it
indirectly.
Sensitivity to acute as well as long-term treatment with
estradiol decreased with age in OVX rats (Figures 2 and 3). This
has been demonstrated previously. Whereas acute treatment with
estradiol both at 5 and 10 µg produced an AD-like effect in
3–month-old OVX rats, only 10 µg had an effect in 14-month-
old OVX rats (Recamier-Carballo et al., 2012). In addition,
differences exist in the acute effects of E2 in the younger and older
rats. In young adult OVX rats, E2 had both rapid as well as effects
that were manifest at a later time on both slowing 5-HT clearance
and on blocking the ability of fluvoxamine to slow 5-HT clearance
(Benmansour et al., 2009, 2012). The AD-like effect of E2 (i.e.,
blockade of 5-HT clearance) is due to ERβ activation whereas E2’s
inhibition of fluvoxamine’s ability to slow serotonin clearance is
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FIGURE 4 | Effects of acute fluvoxamine on SERT function of young adult OVX rat or middle-aged OVX rats at different interval times post-OVX.
Electrochemical recordings were carried out in the CA3 region of the hippocampus of 4m-OVX+2w, 10m-OVX+2w, 10m-OVX+4m, 10m-OVX+8m. Fluvoxamine
(4× the amount of 5-HT) was pressure ejected 60–90 s before the second application of 5-HT. Bar and brackets represent mean T80 value (in seconds) before and
after fluvoxamine application ± SEM (n = 6–9); ∗p < 0.01, paired Student’s t-test comparing post-fluvoxamine value with pre-fluvoxamine value for each group.
One-way ANOVA comparing T80 values pre-fluvoxamine and post-fluvoxamine values in all groups reveals no differences among groups in these two values.
mediated through the ERα receptor subtype (Benmansour et al.,
2012). In middle-aged OVX rats, the effects of E2 on fluvoxamine-
induced blockade of 5-HT clearance were rapid whereas its own
effects on 5-HT clearance were manifest later in time (Figure 2).
Several mechanisms could explain these differential effects
as well as the reduced sensitivity to estradiol with aging, e.g.,
subcellular redistribution of ERα and ERβ in middle age and/or
an age-dependent decline in the number of available ERs. Studies
using aged female animals have shown that the expression of both
ERα and ERβ in the brain change with age in a region specific
manner for each receptor subtype (Foster, 2012); however, both
ER subunit proteins decreased in the hippocampus of aged female
rats (Yamaguchi and Yuri, 2014). This could account, at least
partially, for the reduced potency of estradiol observed in our
experiments using chronoamperometry. In addition to the age-
related changes in ER expression, the ability of estrogen to
regulate ER expression changes with age and is different in each
brain area for each ER subtype (Yamaguchi and Yuri, 2014). It is
also possible that a decline in ERα function, rather than a loss
of receptor expression, could mediate a decrease in estrogen’s
effects with advanced age. Aging was shown to be associated
with the expression of dominant-negative ERα splice variants that
reduced the ability of estradiol treatments to preserve cognition
(Bohacek and Daniel, 2009). Little is known how ER expression
changes in the hippocampus of aging humans. However, and
importantly, elderly women are more likely to express ERα splice
variants that can act as dominant negative regulators, reducing or
inhibiting ERα-mediated transcriptional activity (Ishunina and
Swaab, 2009).
Similarly, several ERβ splice variants have been identified in
the rat hippocampus. One of these, rERβ2, has a low binding
affinity for estradiol and the ability to interact with coactivators
such that it functions as a dominant negative receptor in the rat
(Weiser et al., 2008). rERβ2 expression increased in the brains of
intact rats with age and estropause (Wang et al., 2012). Finally,
estrogen signaling possibly involving either cAMP response
element-binding protein (CREB) or extracellular signal-regulated
kinases (ERK), also changes with age. Age-related decreases in
rapid E2 responses are observed for E2-mediated growth in
synaptic transmission and facilitation of long-term potentiation
(Foy et al., 2008), and activation of ERK (Bi et al., 2003). Also,
the levels of total or phosphorylated CREB are reduced in the
hippocampus of old rats (Kudo et al., 2005). The effect of aging
on CREB seems to be specific for the hippocampus because
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FIGURE 5 | Effect of chronic treatment with sertraline in the FST. OVX rats (4m-OVX+2w, 10m-OVX+2w, 10m-OVX+4m, 10m-OVX+8m) were treated for 2
weeks with sertraline via subcutaneous osmotic minipumps, as described in the Section “Materials and Methods.” Mean counts for immobility, swimming and
climbing behaviors were sampled every 5 s of the swim test period. Bars and brackets represent the mean value ± SEM, n = 8/group. (A) Immobility: Two-way
ANOVAs were carried out between: (1) age and treatment (4m-OVX+2w and 10m-OVX+2w groups) and (2) between time post-OVX and treatment (10m-OVX+2w,
10m-OVX+4m, and 10m-OVX+8m groups). When comparing age/treatment, two-way ANOVA showed a significant main effect for treatment [F(1,28) = 169.53,
p < 0.001] but no significant effect for age or for interaction between age × treatment. When comparing time post-OVX /treatment, two-way ANOVA showed a
significant main effect for treatment [F(1,42) = 70.48, p < 0.001] but no significant effect for time post-OVX or for interaction between time post-OVX × treatment.
Dunnett’s post hoc analysis was carried out; ∗p < 0.001, comparing 10m-OVX+2w with 4m-OVX+2w and 10m-OVX+4m and 10m-OVX+8m with 10m-OVX-2
weeks. (B) Swimming: Two-way ANOVAs were carried out between (1) age and treatment (4m-OVX+2w and 10m-OVX+2w groups) and (2) between time post-OVX
and treatment (10m-OVX+2w, 10m-OVX+4m, and 10m-OVX+8m groups). When comparing age/treatment, two-way ANOVA showed a significant main effect for
age [F(1,28) = 5.24, p < 0.05] and for treatment [F(1,28) = 178.80, p < 0.001] but no significant effect for interaction between age × treatment. When comparing
time post-OVX/treatment, two-way ANOVA showed a significant main effect for treatment [F(1,42) = 70.48, p < 0.001] but no significant effect for time post-OVX or
for interaction between time post-OVX × treatment. Dunnett’s post hoc analysis was carried out;∗p < 0.001, comparing 10m-OVX+2w with 4m-OVX+2w and
10m-OVX+4m and 10m-OVX+8m with 10m-OVX-2 weeks. (C) Climbing: Two-way ANOVAs were carried out between age and treatment and between time
post-OVX and treatment. There were no significant effects in any of the analyses.
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TABLE 1 | Serum levels of sertraline.
4m-OVX+2w 10m OVX+2w 10m-OVX+4m 10m-OVX+8m
Sertraline (ng/ml) 316a ± 28 355 ± 46 609 ± 165 238 ± 29
Desmethyl-sertraline/sertraline (as a ratio) 0.416 ± 0.07 0.533 ± 0.04 0.644 ± 0.05 0.472 ± 0.06
aMean ± SEM.
Serum concentration of sertraline and desmethyl-sertraline were determined after 2 weeks treatment with sertraline (10 mg/kg/day) by subcutaneous osmotic minipumps
implant. Also represented in the table is the ratio of desmethyl-sertraline/sertraline.
A two-way ANOVA analysis age/treatment and time post-OVX /treatment revealed no significant effect.
changes in pCREB were not observed in the frontal cortex of old
rats (Xu et al., 2010). All these factors, then, may be in play in
accounting for our observations of diminished effects of estradiol
in 10-month OVX rats as compared to younger OVX rats.
Studies on the effect of AD treatment using older female
animals are scarce, with most having tested only the effects
of acute treatment with ADs. Consistent with our data, acute
fluoxetine (10 mg/kg) treatment produced an analogous response
in young adult and middle-aged OVX rats in the FST, although
a lower dose 2.5 mg/kg reduced immobility in younger rats
but not in middle-aged females (Recamier-Carballo et al., 2012;
Fernandez-Guasti et al., 2016). In contrast, citalopram (up to
10 mg/kg) given sub-acutely to middle-aged OVX rats had no
effect in the FST (Vega Rivera et al., 2016), although it did
produce an AD-like effect in middle-aged OVX rats that had been
subjected to chronic mild stress (Romano-Torres and Fernandez-
Guasti, 2010). Chronic treatment with fluoxetine had no effect in
middle-aged female mice (Li et al., 2015).
Modulation of 5-HT neurotransmission has long been a
primary pharmacological target for the treatment of depression
and more recently anxiety disorders by SSRIs. SSRIs enhance
synaptic 5-HT action by blocking the reuptake of 5-HT
(Schloss and Williams, 1998). Global enhancement of serotonin
neurotransmission may activate all subtypes of serotonin
receptors in brain, whereas each 5-HT receptor subtype has
different and specific functions in defined brain regions (Polter
and Li, 2011). The process of aging has complex effects on 5-HT
neurotransmission throughout central and peripheral systems.
Although there are no clear alterations in the number of 5-HT
neurons, accumulated evidence suggests aging compromises 5-
HT neurotransmission as well as producing altered expression of
SERT and 5-HT receptors in multiple brain regions (Rodriguez
et al., 2012; Fidalgo et al., 2013). Contradictory results have
been reported on age-related changes in SERT, with decreases,
increases or no change being described (Brunello et al., 1985;
Severson et al., 1985; Owen et al., 1986; Marcusson et al., 1987;
Arranz et al., 1993; Yamamoto et al., 2002). Multiple studies have
demonstrated a decrease in serotonin receptor 1A (5-HT1A),
serotonin receptor 2A (5-HT2A) receptor binding sites/affinity,
protein expression and/or gene expression in the brain with
increasing age (Meltzer et al., 1998, 2001; Tauscher et al., 2001);
however, this has not always been replicated (Parsey et al., 2002).
This variability could be due to the species, the brain area or
the measurement techniques used to quantify SERT and/or 5-
HT receptors (Rodriguez et al., 2012). Little is known, however,
about age-related changes in serotonergic function in females.
In this study, the effect of local application of an SSRI into
the CA3 region of the hippocampus on SERT function was
similar in young adult and middle-aged OVX rats (Figure 4).
Also similar was the effect of sertraline in the FST in all the
groups (Figure 5). Thus, two different measures of the effect
of SSRIs on SERT function gave the same result, namely that
effects were similar in younger and middle aged OVX rats.
Pharmacokinetic changes produced by age could modify the
drug effects. The most significant change is an age-dependent
reduction of renal excretion, caused by deficient glomerular
filtration (Turnheim, 2003; Mangoni and Jackson, 2004). As a
consequence, drug serum levels tend to increase, producing a
stronger pharmacological effect. This was not the case in our
study as in middle-aged OVX rats levels of sertraline and its
metabolite were not significantly different from those measured
in younger OVX rats (Table 1).
Clinical data have been equivocal whether estrogen therapy in
postmenopausal women benefits cognition (Maki, 2012; Daniel,
2013). A reevaluation of the role of estrogens as neuroprotective
agents led to the development of “the critical period” or “window
of opportunity” hypothesis of estrogen effects (Rocca et al.,
2011). This proposes that estrogen therapy is only beneficial if
administration is begun during a time window in close proximity
to menopause (Resnick and Henderson, 2002). An initial study
in rats provided the first suggestion of a critical period for
the efficacy of estrogen (Gibbs, 2000). Initiation of estradiol
treatment immediately or 3 months following ovariectomy in
middle-aged rats enhanced performance on a delayed matching-
to-position maze task whereas no enhancement of performance
was evident if estradiol administration was begun 10 months
after ovariectomy (Gibbs, 2000). Other data also indicated that
beneficial effects of estradiol on cognition, cholinergic function,
and hippocampal plasticity were obtained only when hormone
treatment was initiated at relatively early time points after
ovariectomy (Daniel, 2013).
Many studies have examined the critical period hypothesis
with respect to cognition but only a few clinical studies have
investigated the effect of the time of initiation of ERT and/or AD
therapy after menopause in mood disorders (see Craig, 2013). It
was reported that ERT improved mood in pre-menopausal but
not post-menopausal women (Cohen et al., 2003). There have
been very few preclinical studies as well. A recent study showed
that an AD-like effect induced by acute treatment with ethinyl-
estradiol treatment was found after 1 week but not 3 weeks post-
OVX (Fernandez-Guasti et al., 2016). In middle-aged OVX rats,
estradiol had an AD-like effect in the FST when given at a short
time post-OVX but not when given 5–6 months later (Walf et al.,
2009; Kiss et al., 2012; Wang et al., 2012). Consistent with this, our
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data show that the AD-like effect of estradiol in middle aged rats
was present only when treatment was started 2 weeks post-OVX
but not 4 months post-OVX (Figures 2 and 3). In addition, this
effect was confirmed to be due to the longer time interval post-
OVX and not to aging as 14-month OVX rats displayed an AD-
like effect when tested 2 weeks post-OVX in the FST (Figure 3).
Emerging data implicate a decline in ERα expression or function
in brain resulting from long-term hormone deprivation as a basis
for the existence of the critical period (Foster, 2012). In addition it
was suggested that the C terminus of Hsc70-interacting protein-
mediated degradation of hippocampal ERα may serve as a
molecular mechanism for the critical therapeutic window for
post-menopausal estrogen therapy (Zhang et al., 2011). Another
potential mechanism may be due to increased expression of the
dominant negative ERβ isoform, ERβ2, which correlated with a
significant decrease in swim time in the FST and appears to be
a crucial determinant responsible, at least in part, for the loss of
estrogen response after protracted absence of ovarian hormones
in a rat model of menopause (Wang et al., 2012). Experiments
examining such parameters will be necessary to determine the
mechanisms responsible for the results obtained here after either
acute or chronic treatment with estradiol.
This study also examined if prolonged estrogen deprivation
may reduce the likelihood of SSRIs having an AD-like effect.
It was found that SSRIs have the same efficacy at blocking
SERT function and inducing AD-like effects in the middle-aged
OVX rats tested 2 weeks, 4 months, or 8 months post-OVX
(Figures 4 and 5). Only a few studies have investigated the
critical window for AD effects in middle-aged rats as opposed
to younger OVX rats. In one study, acute citalopram treatment
had no effect in the FST in middle aged-rats independent of the
post OVX interval. The authors concluded that age and endocrine
condition are factors that contribute to decreased sensitivity to
citalopram (Vega Rivera et al., 2016). Treatment with fluoxetine
was reported to be efficacious in depressed middle-aged women
(Amsterdam et al., 1999) and that pre- and post-menopausal
women suffering from depression both responded to citalopram
treatment (Kornstein et al., 2013). However, a poorer response
to AD treatment in post-menopausal women compared to pre-
menopausal women has also been reported (Pae et al., 2009).
CONCLUSION
This study showed that the sensitivity to estradiol decreased
in middle–aged OVX rats compared to younger adult OVX
rats, whereas the AD-like effects of SSRIs was not diminished
in middle-aged OVX rats compared to young adult OVX rats.
The AD-like effect of estradiol, in contrast to that of SSRIs,
is subject to a critical period. In addition despite the potential
benefits of estradiol treatment, hormone replacement therapy
presents unwanted health risks, particularly in older post-
menopausal women (Lukes, 2008). Findings from the Women’s
Health Initiative trial show that HRT in healthy postmenopausal
women is associated with an elevated risk of breast cancer
and coronary heart disease (Rossouw et al., 2002). In addition,
the risk of breast cancer increases with longer exposure to
HRT, limiting long-term use (Rossouw et al., 2002; Anderson
et al., 2006). An additional disadvantage of estradiol treatment
is that estradiol act as a non-selective ER agonist. ERα and ERβ
appear to have opposing functions in several brain areas. As
shown previously, ERβ mediates the AD-like effect of estradiol
whereas ERα mediates its blockade of the AD-like effect of SSRIs
(Benmansour et al., 2012); and that could result in diminishing
therapeutic potential of estradiol. Thus, if our results in rats can
be translated to the clinical situation, they indicate that SSRIs
have essentially identical effects on the SERT in females regardless
of age and the time of treatment initiation after menopause.
However, if estradiol is to be tried in postmenopausal women
suffering from depression, our results suggest that it might only
be helpful to those in perimenopause or shortly after menopause
begins.
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